AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC
AstraZeneca and Hutchison China MediTech (Chi-Med) have started a Phase III SAVOIR clinical trial of savolitinib to treat patients with papillary renal cell carcinoma (PRCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Cancer & Oncology | Carcinoma | China Health | Clinical Trials | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma